Clinical trials: Cushing Syndrome
Endocrine Diseases
Evaluation of Adults With Endocrine and Metabolic-Related Conditions
Background: There are many endocrine and metabolic-related conditions. Two well-known disorders include diabetes and thyroid disease. Some of these diseases are caused by a change in genes.
- Trial name
- NCT02830308
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy, Involutional Depression
Dynamics of Leptin and Endocrine Function
This is a study investigating the hormones and substances important to the stress response. The hormone that is most directly responsible for stress response is called corticotropin-releasing hormone (CRH).
- Trial name
- NCT00001543
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Hypercortisolism
Effects of Metyrapone in Patients With Hypercortisolism
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers…
- Trial name
- CEM (NCT05255900)
- Testing
- Metyrapone Capsules
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Auxologico Italiano
Cushing Syndrome, Cushing Disease
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an…
- Conditions
- Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
- Trial name
- NCT05804669
- Testing
- atumelnant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Adrenal Insufficiency, Congenital Adrenal Hyperplasia
Dynamic Hormone Diagnostics in Endocrine Disease
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary…
- Conditions
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome, Growth Hormone Deficiency
- Trial name
- ultradian (NCT02934399)
- Testing
- 27 hour subcutaneous fluid sampling
- Where
- 4 sites in Greece, Norway and 2 more
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
- Conditions
- Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
- Trial name
- ACSPIRE (NCT05436639)
- Testing
- SPI-62 dose
- Where
- 5 sites in United States, Romania and 1 more
- Volunteers
- 30 people
- Sponsor
- Sparrow Pharmaceuticals
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
Cushing Syndrome, Neoplasms
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.
- Trial name
- NCT05347979
- Testing
- Dabigatran Etexilate, Relacorilant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics